A backbone-cyclic, receptor 5-selective somatostatin analogue: Synthesis, bioactivity, and nuclear magnetic resonance conformational analysis

Chaim Gilon, Martin Huenges, Barbara Matha, Gary Gellerman, Vered Hornik, Michel Afargan, Oved Amitay, Ofer Ziv, Etty Feller, Asher Gamliel, Dvira Shohat, Mazal Wanger, Oded Arad, Horst Kessler

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Abstract

Cyclo(PheN2-Tyr-D-Trp-Lys-Val-PheC3)-Thr-NH2 (PTR 3046), a backbone- cyclic somatostatin analogue, was synthesized by solid-phase methodology. The binding characteristics of PTR 3046 to the different somatostatin receptors, expressed in CHO cells, indicate high selectivity to the SSTR5 receptor. PTR 3046 is highly stable against enzymatic degradation as determined in vitro by incubation with rat renal homogenate and human serum. The biological activity of PTR 3046 in vivo was determined in rats. PTR 3046 inhibits bombesin- and caerulein-induced amylase and lipase release from the pancreas without inhibiting growth hormone or glucagon release. The major conformation of PTR 3046 in CD3OH, as determined by NMR, is defined by a type II' β-turn at D- Trp-Lys and a cis amide bond at Val-PheC3.

Original languageEnglish
Pages (from-to)919-929
Number of pages11
JournalJournal of Medicinal Chemistry
Volume41
Issue number6
DOIs
StatePublished - 12 Mar 1998

Fingerprint

Dive into the research topics of 'A backbone-cyclic, receptor 5-selective somatostatin analogue: Synthesis, bioactivity, and nuclear magnetic resonance conformational analysis'. Together they form a unique fingerprint.

Cite this